Wesper Journal

Revolutionizing Obstructive Sleep Apnea Care with Zepbound

Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.

Zepbound Gains Approval for Sleep Apnea Coverage

Zepbound (tirzepatide) has received FDA approval for the treatment of obstructive sleep apnea, now included in Medicare coverage to help manage the condition alongside obesity. This approval marks a shift towards a holistic approach, combining medication with real-time monitoring for...

Previous 1 2

our research

The Wesper Journal is our weekly publication dedicated to exploring sleep apnea, sleep health, and the latest updates from Wesper. Each edition offers expert insights, practical tips, and valuable resources to help you better understand and improve your sleep, empowering you to take control of your sleep health journey.

Wesper Featured on CNET

The most important health tech of...

READ

Helix Wesper: The Most Advanced Data Analysis Solution

Completed by Dr. Chelsie Rohrscheibchelsie@wesper.co Jan 06,...

READ

OSA – Missed or Misdiagnosed?

he CDC estimates that nearly 20%...

READ